Jee Bang

View Scopus Profile

Research activity per year

25 Article
4 Comment/debate
2 Editorial
2 Review article

4 results

Filter

2024
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)
Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., Oakes, D., Siemers, E., Kieburtz, K. D., Zauderer, M., Kayson, E., Goldstein, J., Barbano, R., Marder, K., Dayalu, P. & Rosas, H. D. & 31 others, Kostyk, S., Kamholz, J., Racette, B., Bang, J., Claassen, D., McDonell, K., Factor, S., Walker, F., Goas, C., Wojcieszek, J., Raymond, L. A., Corey-Bloom, J., Sung, V., Dean, M., Geshwind, M., Nelson, A., Frank, S., LaFaver, K., Duker, A., Elmer, L., Samii, A., Lin, Y. H., Chouinard, S., Seeberger, L., Scott, B., Boyd, J., McFarland, N., Stimming, E. F., Suchowersky, O., Testa, C. & Anderson, K., Feb 2024, In: Nature medicine. 30, 2, p. 606 1 p.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
2023
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)
PASSPORT Study Group, Nov 2023, In: Nature medicine. 29, 11, p. 2955-2956 2 p.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
2021

Suicide and Lewy body dementia: Report of a Lewy body dementia association working group
Armstrong, M. J., Sullivan, J. L., Amodeo, K., Lunde, A., Tsuang, D. W., Reger, M. A., Conwell, Y., Ritter, A., Bang, J., Onyike, C. U., Mari, Z., Corsentino, P. & Taylor, A., Mar 2021, In: International journal of geriatric psychiatry. 36, 3, p. 373-382 10 p.
Research output: Contribution to journal › Comment/debate › peer-review
2017

Potential biomarker breakthrough for Huntington's disease
Ross, C. A. & Bang, J., Aug 2017, In: The Lancet Neurology. 16, 8, p. 573-574 2 p.
Research output: Contribution to journal › Comment/debate › peer-review

Jee Bang

Research output

Search results

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)

Suicide and Lewy body dementia: Report of a Lewy body dementia association working group

Potential biomarker breakthrough for Huntington's disease